{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T09:21:15Z","timestamp":1772616075886,"version":"3.50.1"},"reference-count":59,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Data on the immunosuppressants azathioprine (AZA) and mycophenolate mofetil (MMF) in autoimmune cytopenia (AIC) are limited, and no direct comparison exists. We analyzed the failure-free survival (FFS; time from AZA\/MMF initiation to another non\u2013first-line treatment, or death) of both treatments in the prospective nationwide pediatric OBS\u2019CEREVANCE cohort. We included 343 patients (chronic immune thrombocytopenia, n = 161; autoimmune hemolytic anemia, n = 74; Evans syndrome, n = 108). They received AZA (n = 276) or MMF (n = 104; 37 sequentially received both) as monotherapy for a median duration of 11.3 (range, 0.01-149.0) months. Older age was associated with higher FFS for AZA, whereas secondary AIC was associated with higher FFS for MMF. AIC type had no effect. In a propensity score (PS)-matched cohort, AZA and MMF showed similar FFS (adjusted hazard ratio, 0.91; 95% confidence interval, 0.54-1.52; P = .71), with 1-year FFS rates of 73% and 76%, respectively. In subgroup analyses, AZA was associated with higher FFS in PS-matched patients diagnosed at an age of \u226510 years, whereas MMF was associated with higher FFS in PS-matched patients diagnosed at an age of &amp;lt;10 years and in those with confirmed secondary AIC (although with suboptimal matching). Rates of grade \u22653 infection were similar between the 2 drugs, at \u223c2% new cases per year. In summary, AZA and MMF demonstrated comparable overall FFS and infection risk. However, our data suggest that AZA may be more beneficial in children diagnosed at an age of \u226510 years, whereas MMF may be more beneficial in those diagnosed at an age of &amp;lt;10 years and possibly in patients with secondary AIC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017536","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T21:25:53Z","timestamp":1760563553000},"page":"563-574","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Azathioprine or mycophenolate mofetil for pediatric autoimmune cytopenia: a propensity score\u2013matched study"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9412-333X","authenticated-orcid":false,"given":"Thomas","family":"Pincez","sequence":"first","affiliation":[{"name":"1Centre de R\u00e9f\u00e9rence National des Cytop\u00e9nies Auto-immunes de l'Enfant, Bordeaux, France"},{"name":"2Service d'h\u00e9matologie-oncologie, Centre de canc\u00e9rologie Charles Bruneau, Centre Hospitalier Universitaire Sainte-Justine, Centre de Recherche Azrieli du Centre Hospitalier Universitaire Sainte-Justine, D\u00e9partement de p\u00e9diatrie, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helder","family":"Fernandes","sequence":"additional","affiliation":[{"name":"1Centre de R\u00e9f\u00e9rence National des Cytop\u00e9nies Auto-immunes de l'Enfant, Bordeaux, France"},{"name":"3Service d'h\u00e9mato-oncologie, Centre d'investigation clinique de Bordeaux (CIC1401), INSERM CICP, H\u00f4pital Pellegrin, Centre hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Leverger","sequence":"additional","affiliation":[{"name":"4Service d'h\u00e9mato-immuno-oncologie, H\u00f4pital Armand Trousseau, Assistance Publique-H\u00f4pitaux de Paris, Sorbonne Universit\u00e9 Paris, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9645-3968","authenticated-orcid":false,"given":"Vincent","family":"Barlogis","sequence":"additional","affiliation":[{"name":"5D\u00e9partement d'h\u00e9matologie p\u00e9diatrique, h\u00f4pital La Timone, Centre Hospitalier Universitaire de Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mony","family":"Fahd","sequence":"additional","affiliation":[{"name":"6Service d'immuno-h\u00e9matologie, H\u00f4pital Robert-Debr\u00e9, Assistance Publique-H\u00f4pitaux de Paris, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Garnier","sequence":"additional","affiliation":[{"name":"7Institut d'h\u00e9matologie et d'oncologie p\u00e9diatrique, Hospices Civils de Lyon, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Paillard","sequence":"additional","affiliation":[{"name":"8D\u00e9partement d'h\u00e9matoloige et oncologie p\u00e9diatrique, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Guitton","sequence":"additional","affiliation":[{"name":"9Service de p\u00e9diatrie, H\u00f4pital Bic\u00eatre, Assistance Publique-H\u00f4pitaux de Paris, Le Kremlin-Bic\u00eatre, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wadih","family":"Abou Chahla","sequence":"additional","affiliation":[{"name":"10D\u00e9partment d'h\u00e9matologie p\u00e9diatrique, h\u00f4pital Jeanne de Flandre, Centre Hospitalier Universitaire de Lille, Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6919-8383","authenticated-orcid":false,"given":"Marl\u00e8ne","family":"Pasquet","sequence":"additional","affiliation":[{"name":"11H\u00e9matologie immunologie oncologie p\u00e9diatrique, H\u00f4pital des enfants de Toulouse, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0318-3044","authenticated-orcid":false,"given":"Eric","family":"Jeziorski","sequence":"additional","affiliation":[{"name":"12H\u00e9matologie Oncologie P\u00e9diatrique, H\u00f4pital Arnaud de Villeneuve, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9087-4411","authenticated-orcid":false,"given":"Martin","family":"Castelle","sequence":"additional","affiliation":[{"name":"13Unit\u00e9 d'immuno-h\u00e9matologie et rhumatologie p\u00e9diatrique, H\u00f4pital Necked-Enfants Malades, Assistance Publique-H\u00f4pitaux de Paris, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Bayart","sequence":"additional","affiliation":[{"name":"14Unit\u00e9 d'h\u00e9matologie p\u00e9diatrique, Centre Hospitalier Universitaire de Rennes, Hospital, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7988-4712","authenticated-orcid":false,"given":"Isabelle","family":"Pellier","sequence":"additional","affiliation":[{"name":"15Service d'h\u00e9mato-oncologie et immunologie p\u00e9diatrique, Centre Hospitalier Universitaire d'Angers, Centre de Recherche en Canc\u00e9rologie et Immunologie Int\u00e9gr\u00e9 de Nantes et Angers (CRCI2NA), UMR INSERM CNRS, Universit\u00e9 d'Angers, Universit\u00e9 de Nantes, Angers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Thomas","sequence":"additional","affiliation":[{"name":"16Unit\u00e9 d'h\u00e9matologie p\u00e9diatrique, Centre Hospitalier Universitaire de Nantes, Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Pagnier","sequence":"additional","affiliation":[{"name":"17H\u00e9matologie oncologie p\u00e9daitrique, Centre Hospitalier Universitaire de Grenoble, Grenoble, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joy","family":"Benadiba","sequence":"additional","affiliation":[{"name":"18D\u00e9partement d'h\u00e9matologie-oncologie p\u00e9diatrique, Centre Hospitalier Universitaire de Nice, Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Li Thiao Te","sequence":"additional","affiliation":[{"name":"19D\u00e9partement d'h\u00e9matologie\/oncologie p\u00e9diatrique, Centre Hospitalier Universitaire d'Amiens, Amiens, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3403-3842","authenticated-orcid":false,"given":"Nathalie","family":"Cheikh","sequence":"additional","affiliation":[{"name":"20D\u00e9partement d'h\u00e9matologie-oncologie p\u00e9diatrique, Centre Hospitalier Universitaire de Besan\u00e7on, Besan\u00e7on, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Lejeune","sequence":"additional","affiliation":[{"name":"21D\u00e9partement d'h\u00e9matologi-oncologie p\u00e9daitrique, Centre Hospitalier Universitaire de Tours, Tours, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Deparis","sequence":"additional","affiliation":[{"name":"22D\u00e9partement d'h\u00e9matologie-oncologie p\u00e9diatrique, Centre Hospitalier Universitaire de Caen, Caen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude","family":"Marie-Cardine","sequence":"additional","affiliation":[{"name":"23D\u00e9aprtement d'h\u00e9matologie et oncologie p\u00e9diatrique, Centre Hospitalier Universitaire de Rouen, Rouen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Chastagner","sequence":"additional","affiliation":[{"name":"24D\u00e9partement d'h\u00e9matologie-oncologie p\u00e9diatrique, Centre Hospitalier Universitaire de Nancy, Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Desplantes","sequence":"additional","affiliation":[{"name":"25D\u00e9partement de p\u00e9diatrie, Centre Hospitalier Universitaire de Dijon, Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8912-4776","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Millot","sequence":"additional","affiliation":[{"name":"26D\u00e9partment d'h\u00e9matologie p\u00e9diatrique, Centre Hospitalier Universitaire de Poitiers, Poitiers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Vic","sequence":"additional","affiliation":[{"name":"27D\u00e9partement de P\u00e9diatrie, H\u00f4pital de Cornouailles, Quimper, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Thouvenin","sequence":"additional","affiliation":[{"name":"28D\u00e9partment d'oncologie p\u00e9daitrique, Centre Hospitalier Universitaire de Saint-Etienne, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Piguet","sequence":"additional","affiliation":[{"name":"29H\u00e9matologie oncologie p\u00e9diatrique, Centre Hospitalier Universitaire de Limoges, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Pluchart","sequence":"additional","affiliation":[{"name":"30Unit\u00e9 d'h\u00e9matologie-oncologie p\u00e9diatrique, Institut Jean Godinot, Centre Hospitalier Universitaire de Reims, Reims, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Leblanc","sequence":"additional","affiliation":[{"name":"6Service d'immuno-h\u00e9matologie, H\u00f4pital Robert-Debr\u00e9, Assistance Publique-H\u00f4pitaux de Paris, Paris, France"},{"name":"31Universit\u00e9 Paris-Cit\u00e9, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0384-6370","authenticated-orcid":false,"given":"S\u00e9bastien","family":"H\u00e9ritier","sequence":"additional","affiliation":[{"name":"4Service d'h\u00e9mato-immuno-oncologie, H\u00f4pital Armand Trousseau, Assistance Publique-H\u00f4pitaux de Paris, Sorbonne Universit\u00e9 Paris, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0231-4460","authenticated-orcid":false,"given":"Nathalie","family":"Aladjidi","sequence":"additional","affiliation":[{"name":"1Centre de R\u00e9f\u00e9rence National des Cytop\u00e9nies Auto-immunes de l'Enfant, Bordeaux, France"},{"name":"3Service d'h\u00e9mato-oncologie, Centre d'investigation clinique de Bordeaux (CIC1401), INSERM CICP, H\u00f4pital Pellegrin, Centre hospitalier Universitaire de Bordeaux, Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"issue":"1","key":"2026021015515265400_bib1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/bjh.19073","article-title":"Paediatric-onset Evans syndrome: breaking away from refractory immune thrombocytopenia","volume":"203","author":"Aladjidi","year":"2023","journal-title":"Br J Haematol"},{"issue":"6","key":"2026021015515265400_bib2","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood.2020006480","article-title":"An update on pediatric immune thrombocytopenia (ITP): differentiating primary ITP, IPD, and PID","volume":"140","author":"Grace","year":"2022","journal-title":"Blood"},{"issue":"16","key":"2026021015515265400_bib3","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1182\/blood.2023021884","article-title":"Antinuclear antibody\u2013associated autoimmune cytopenia in childhood is a risk factor for systemic lupus erythematosus","volume":"143","author":"Granel","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2026021015515265400_bib4","doi-asserted-by":"crossref","first-page":"e29023","DOI":"10.1002\/pbc.29023","article-title":"Quality of life is an important indication for second-line treatment in children with immune thrombocytopenia","volume":"68","author":"Shimano","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2026021015515265400_bib5","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/bjh.16448","article-title":"Second-line treatment trends and long-term outcomes of 392 children with chronic immune thrombocytopenic purpura: the French experience over the past 25 years","volume":"189","author":"Ducassou","year":"2020","journal-title":"Br J Haematol"},{"issue":"6","key":"2026021015515265400_bib6","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ajh.26900","article-title":"Impact of age at diagnosis, sex, and immunopathological manifestations in 886 patients with pediatric chronic immune thrombocytopenia","volume":"98","author":"Pincez","year":"2023","journal-title":"Am J Hematol"},{"issue":"5","key":"2026021015515265400_bib7","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3324\/haematol.2010.036053","article-title":"New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children","volume":"96","author":"Aladjidi","year":"2011","journal-title":"Haematologica"},{"issue":"2","key":"2026021015515265400_bib8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3324\/haematol.2020.271106","article-title":"Long term follow-up of pediatric-onset Evans syndrome: broad immunopathological manifestations and high treatment burden","volume":"107","author":"Pincez","year":"2022","journal-title":"Haematologica"},{"issue":"23","key":"2026021015515265400_bib9","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"issue":"22","key":"2026021015515265400_bib10","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"issue":"10004","key":"2026021015515265400_bib11","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(15)61107-2","article-title":"Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial","volume":"386","author":"Grainger","year":"2015","journal-title":"Lancet Lond Engl"},{"issue":"5","key":"2026021015515265400_bib12","doi-asserted-by":"crossref","first-page":"e36698","DOI":"10.1371\/journal.pone.0036698","article-title":"Rituximab for children with immune thrombocytopenia: a systematic review","volume":"7","author":"Liang","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"2026021015515265400_bib13","doi-asserted-by":"crossref","first-page":"e29447","DOI":"10.1002\/pbc.29447","article-title":"Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: a systematic review and meta-analysis of prospective clinical trials","volume":"69","author":"Ayad","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2026021015515265400_bib14","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/bjh.14627","article-title":"Benefits of rituximab as a second-line treatment for autoimmune haemolytic anaemia in children: a prospective French cohort study","volume":"177","author":"Ducassou","year":"2017","journal-title":"Br J Haematol"},{"issue":"7","key":"2026021015515265400_bib15","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/ajh.27337","article-title":"Pediatric refractory chronic immune thrombocytopenia: identification, patients\u2019 characteristics, and outcome","volume":"99","author":"Pincez","year":"2024","journal-title":"Am J Hematol"},{"issue":"3","key":"2026021015515265400_bib16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41584-020-0374-8","article-title":"Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology","volume":"16","author":"Broen","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"2-3","key":"2026021015515265400_bib17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"issue":"2","key":"2026021015515265400_bib18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin Hematol"},{"issue":"4","key":"2026021015515265400_bib19","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bjh.13622","article-title":"Mycophenolate mofetil therapy for severe immune thrombocytopenia","volume":"171","author":"Taylor","year":"2015","journal-title":"Br J Haematol"},{"issue":"2","key":"2026021015515265400_bib20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/bjh.13533","article-title":"Mycophenolate mofetil and Sirolimus as second or further line treatment in children with chronic refractory primitive or secondary autoimmune cytopenias: a single centre experience","volume":"171","author":"Miano","year":"2015","journal-title":"Br J Haematol"},{"issue":"3","key":"2026021015515265400_bib21","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/bjh.14261","article-title":"Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian association of paediatric haematology\/oncology","volume":"175","author":"Miano","year":"2016","journal-title":"Br J Haematol"},{"issue":"10","key":"2026021015515265400_bib22","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2100596","article-title":"Mycophenolate mofetil for first-line treatment of immune thrombocytopenia","volume":"385","author":"Bradbury","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"2026021015515265400_bib23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3109\/09537104.2010.520372","article-title":"Mycophenolate mophetil therapy for chronic immune thrombocytopenic purpura resistant to steroids, immunosuppressants, and\/or splenectomy in adults","volume":"22","author":"Colovi\u0107","year":"2011","journal-title":"Platelets"},{"issue":"3","key":"2026021015515265400_bib24","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1365-2141.2002.03430.x","article-title":"Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura","volume":"117","author":"Howard","year":"2002","journal-title":"Br J Haematol"},{"issue":"5","key":"2026021015515265400_bib25","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1745-7254.2005.00088.x","article-title":"Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenic purpura","volume":"26","author":"Zhang","year":"2005","journal-title":"Acta Pharmacol Sin"},{"issue":"6","key":"2026021015515265400_bib26","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1034\/j.1600-0609.2003.00076.x","article-title":"Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura","volume":"70","author":"Hou","year":"2003","journal-title":"Eur J Haematol"},{"issue":"1","key":"2026021015515265400_bib27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/ajh.20515","article-title":"Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura","volume":"81","author":"Provan","year":"2006","journal-title":"Am J Hematol"},{"issue":"1","key":"2026021015515265400_bib28","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1600-0609.2005.00437.x","article-title":"Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study","volume":"75","author":"Kotb","year":"2005","journal-title":"Eur J Haematol"},{"issue":"2","key":"2026021015515265400_bib29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2141.1990.tb02569.x","article-title":"Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases","volume":"74","author":"Quiquandon","year":"1990","journal-title":"Br J Haematol"},{"key":"2026021015515265400_bib30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jpeds.2020.12.018","article-title":"Prospective evaluation of the first option, second-line therapy in childhood chronic immune thrombocytopenia: splenectomy or immunomodulation","volume":"231","author":"Ducassou","year":"2021","journal-title":"J Pediatr"},{"issue":"1","key":"2026021015515265400_bib31","doi-asserted-by":"crossref","first-page":"100035","DOI":"10.1016\/j.bvth.2024.100035","article-title":"Role of azathioprine in the management of ITP in the TPO-RA era: a single centre retrospective study","volume":"2","author":"Le-Nguyen","year":"2025","journal-title":"Blood Vessel Thromb Hemost"},{"issue":"12","key":"2026021015515265400_bib32","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models","volume":"163","author":"Brookhart","year":"2006","journal-title":"Am J Epidemiol"},{"issue":"25","key":"2026021015515265400_bib33","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"10392","key":"2026021015515265400_bib34","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(23)00329-X","article-title":"Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study","volume":"401","author":"de Masson","year":"2023","journal-title":"The Lancet"},{"issue":"12","key":"2026021015515265400_bib35","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood-2016-03-603365","article-title":"How I treat refractory immune thrombocytopenia","volume":"128","author":"Cuker","year":"2016","journal-title":"Blood"},{"issue":"19","key":"2026021015515265400_bib36","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1182\/blood-2014-06-583021","article-title":"Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients","volume":"124","author":"Barcellini","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2026021015515265400_bib37","doi-asserted-by":"crossref","first-page":"E150","DOI":"10.1002\/ajh.23767","article-title":"Characteristics and outcome of warm autoimmune hemolytic anemia in adults: new insights based on a single-center experience with 60 patients","volume":"89","author":"Roumier","year":"2014","journal-title":"Am J Hematol"},{"issue":"4","key":"2026021015515265400_bib38","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1001\/jama.1967.03130170059006","article-title":"Azathioprine in refractory idiopathic thrombocytopenic purpura","volume":"202","author":"Sussman","year":"1967","journal-title":"JAMA"},{"issue":"1","key":"2026021015515265400_bib39","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1600-0609.1973.tb00035.x","article-title":"Evaluation of azathioprine in autoimmune thrombocytopenia and lupus erythematosus","volume":"10","author":"Goebel","year":"1973","journal-title":"Scand J Haematol"},{"issue":"3","key":"2026021015515265400_bib40","first-page":"217","article-title":"Safety and efficacy of azathioprine in immune thrombocytopenia","volume":"11","author":"Mishra","year":"2021","journal-title":"Am J Blood Res"},{"issue":"2","key":"2026021015515265400_bib41","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10067-023-06820-4","article-title":"Efficacy and safety of mycophenolate mofetil in patients with immune thrombocytopenic purpura: a systematic review and meta-analysis","volume":"43","author":"Abdelwahab","year":"2024","journal-title":"Clin Rheumatol"},{"key":"2026021015515265400_bib42","doi-asserted-by":"crossref","first-page":"1174671","DOI":"10.3389\/fped.2023.1174671","article-title":"Mycophenolate mofetil for autoimmune cytopenias in children: high rates of response in inborn errors of immunity","volume":"11","author":"Berrueco","year":"2023","journal-title":"Front Pediatr"},{"issue":"4","key":"2026021015515265400_bib43","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1365-2141.2005.05496.x","article-title":"Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome","volume":"129","author":"Rao","year":"2005","journal-title":"Br J Haematol"},{"issue":"22","key":"2026021015515265400_bib44","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2014-04-570127","article-title":"Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis","volume":"124","author":"Heitink-Poll\u00e9","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2026021015515265400_bib45","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.immuni.2023.06.008","article-title":"Site-specific development and progressive maturation of human tissue-resident memory T cells over infancy and childhood","volume":"56","author":"Connors","year":"2023","journal-title":"Immunity"},{"issue":"6","key":"2026021015515265400_bib46","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/ibd.20387","article-title":"Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger","volume":"14","author":"Grossman","year":"2008","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"2026021015515265400_bib47","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ijpharm.2013.08.061","article-title":"MODRIC - manipulation of drugs in children","volume":"457","author":"Richey","year":"2013","journal-title":"Int J Pharm"},{"key":"2026021015515265400_bib48","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejpb.2020.10.013","article-title":"Assessment of practices for suspended oral drugs by tablet crushing in pediatric units","volume":"157","author":"Nguyen","year":"2020","journal-title":"Eur J Pharm Biopharm"},{"issue":"4","key":"2026021015515265400_bib49","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2125.2010.03867.x","article-title":"Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy","volume":"71","author":"Adam de Beaumais","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"21","key":"2026021015515265400_bib50","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis","volume":"353","author":"Ginzler","year":"2005","journal-title":"N Engl J Med"},{"issue":"5","key":"2026021015515265400_bib51","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"2026021015515265400_bib52","doi-asserted-by":"crossref","first-page":"e2432131","DOI":"10.1001\/jamanetworkopen.2024.32131","article-title":"Mycophenolate mofetil and new-onset systemic lupus erythematosus: a randomized clinical trial","volume":"7","author":"You","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2026021015515265400_bib53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2018-11-887141","article-title":"Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes","volume":"134","author":"Hadjadj","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2026021015515265400_bib54","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/FTD.0b013e3181dbd712","article-title":"Monitoring of azathioprine metabolites in pediatric patients with autoimmune hepatitis","volume":"32","author":"Nguyen","year":"2010","journal-title":"Ther Drug Monit"},{"issue":"11","key":"2026021015515265400_bib55","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1093\/ndt\/gfn497","article-title":"Therapeutic drug monitoring for mycophenolic acid in patients with autoimmune diseases","volume":"23","author":"de Winter","year":"2008","journal-title":"Nephrol Dial Transpl"},{"issue":"5","key":"2026021015515265400_bib56","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cgh.2014.05.015","article-title":"Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis","volume":"13","author":"Kotlyar","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"32","key":"2026021015515265400_bib57","doi-asserted-by":"crossref","first-page":"33849","DOI":"10.18632\/oncotarget.5292","article-title":"Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage","volume":"6","author":"Crane","year":"2015","journal-title":"Oncotarget"},{"issue":"12","key":"2026021015515265400_bib58","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1111\/j.1600-6143.2005.01125.x","article-title":"Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil","volume":"5","author":"Robson","year":"2005","journal-title":"Am J Transpl"},{"key":"2026021015515265400_bib59","doi-asserted-by":"crossref","first-page":"1415389","DOI":"10.3389\/fimmu.2024.1415389","article-title":"Infection risk in patients with autoimmune cytopenias and immune dysregulation treated with mycophenolate mofetil and sirolimus","volume":"15","author":"Comella","year":"2024","journal-title":"Front Immunol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/3\/563\/2500560\/blooda_adv-2025-017536-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/3\/563\/2500560\/blooda_adv-2025-017536-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T20:52:08Z","timestamp":1770756728000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/3\/563\/547811\/Azathioprine-or-mycophenolate-mofetil-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017536","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,10]]},"published":{"date-parts":[[2026,1,28]]}}}